Asymmetric Catalysis Allows Controlled Synthesis of Biologically Active Molecules
For his outstanding research contributions to catalytic processes in synthesis of biologically active molecules, Professor Dr Nicolai Cramer is receiving the BASF Catalysis Award 2013. Professor Cramer heads the laboratory of asymmetric catalysis and synthesis at the École Polytechnique Fédérale (EPF) in Lausanne, Switzerland. The prize, worth €10,000, was presented by Dr. Andreas Kreimeyer, Member of the Board of Executive Directors of BASF SE and Research Executive Director, at the “Heidelberg Forum of Molecular Catalysis,” a symposium of international experts organized jointly by Heidelberg University, Collaborative Research Center 623 “Molecular Catalysts” and BASF SE.
“Catalysis is an important key technology for the chemical industry and is an indispensable tool for accessing new feedstocks and developing new energy efficient production processes,” said Kreimeyer. As a company with a leading international research and development platform for catalysts, BASF therefore attaches particular importance to promoting excellent young researchers in this field.
With his research group centered at EPF Lausanne, Professor Cramer is working particularly in the field of enantioselective metal-catalyzed transformations and their implementation for the synthesis of complex biologically active molecules. The Cramer lab works on the development of broadly applicable catalytic methods for the selective functionalization of relatively inert C-H and C-C bonds with different transition-metal complexes.
“We are developing precise tools for all fields that produce molecules with high reactivity and selectivity. Our methods are suited for a faster synthesis because in medical research it is also essential to produce possible active ingredients rapidly. In this way, we have synthesized and identified molecules that show an anti-HIV effect. In doing this we closely collaborate with the life sciences faculty in Lausanne,” explained the prize winner Nicolai Cramer. “But other interesting fields also exist such as material sciences in which we can provide a better approach to molecules that for example are used for organic electronics.”
The “Heidelberg Forum of Molecular Catalysis,” an international scientific symposium of top class researchers based at Heidelberg University, is being held this year for the seventh time. The event offers scientists from academia and industry the opportunity to exchange news and information about the latest research activities in molecular catalysis. Plenary presentations are being held this year not only by the prizewinner but also by Professors Stephen L. Buchwald, MIT, Cambridge, Massachusetts, Peter Chen, ETH Zürich, Switzerland, and the Nobel Prize laureate Ei-ichi Negishi, Purdue University, Indiana.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...